Imunon, Inc. 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; compared with fiscal 2021. Imunon, formerly Celsion Corporation, changed its name and ticker to IMNN in September 2022. The company is a clinical-stage biotechnology business with no product sales.
Business context and programs
- IMNN-001: Phase II DNA-based immunotherapy for advanced ovarian cancer, studied with standard chemotherapy. The OVATION 2 trial completed enrollment of 110 patients in September 2022; topline results were expected in the first half of 2024.
- PLACCINE: Preclinical DNA vaccine platform. The filing reports encouraging mouse and non-human-primate findings for SARS-CoV-2, but no human testing had begun. Management planned a pre-IND meeting and selection of another pathogen target in 2023.
- ThermoDox: The Phase III OPTIMA study in liver cancer was discontinued after a futility boundary was crossed; the company stopped follow-up in 2021.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0.5 million | $0.5 million |
| Research and development expense | $11.7 million | $10.6 million |
| General and administrative expense | $13.7 million | $10.9 million |
| Operating loss | $24.9 million | $21.0 million |
| Net loss | $35.9 million | $20.8 million |
| Basic and diluted loss per share | $5.03 | $3.83 |
| Net cash used in operating activities | $23.1 million | $16.2 million |
The $0.5 million revenue was scheduled recognition of a Hisun technology-development fee, not product sales; the agreement was fully amortized by year-end 2022. Gross margin is not a meaningful operating measure for this development-stage company.
- At December 31, 2022, current assets were $37.2 million, current liabilities $10.0 million, and working capital $27.1 million. Cash and cash equivalents were $11.5 million; available-for-sale debt securities were $21.3 million.
- The company reported $6.0 million of restricted cash securing its Silicon Valley Bank (SVB) loan. Notes payable had a $6.0 million principal balance, with $1.4 million current and $4.6 million non-current net of financing costs on the balance sheet.
- Management estimated resources would fund operations into 2025. It also stated that substantial additional capital will be needed to advance development and that financing may be dilutive or unavailable on acceptable terms.
Changes, unusual items, and outlook
- Net loss increased by $15.1 million. Key factors included a $13.4 million non-cash impairment of in-process research and development (IPR&D), higher G&A and $5.0 million of interest expense. Interest expense included $4.6 million related to the 2022 convertible preferred-stock financing.
- The company recorded a $5.4 million non-cash gain after writing off the EGEN earn-out liability because the milestone requirements were not achieved. The $1.6 million income-tax benefit related to selling New Jersey net operating losses.
- R&D expense rose $1.1 million, chiefly as IMNN-001 and PLACCINE development costs increased; ThermoDox-related manufacturing costs declined. G&A rose $2.8 million, primarily due to professional fees and staffing costs.
- In January 2022, the company raised $28.5 million through preferred stock, then redeemed the preferred shares for $28.5 million in March. It raised $7.0 million gross in an April common-stock offering and received about $0.5 million net from ATM share sales late in 2022. Common shares issued increased from 5.77 million to 7.44 million during the year; 9.09 million were outstanding as of March 28, 2023.
- SVB was placed into FDIC receivership in March 2023. The filing noted uncertainty about access to the credit facility, although the $6.0 million loan was secured by an equal amount of restricted cash. The loan carried a variable rate reported as 7.75% and scheduled amortization began in 2023.
- Management reported no material disruption to ongoing trials as of the filing, but identified clinical, regulatory, financing, third-party manufacturing, patient-enrollment, competition, and intellectual-property risks. No product revenue is expected for the next several years, if ever.
Investor facts to verify
- Whether OVATION 2 topline results were reported as expected, and whether the randomized trial’s endpoints support further development or regulatory discussions.
- How much usable liquidity remains after restricted cash, operating burn, and debt service, and whether the stated runway into 2025 remains achievable.
- The status and terms of subsequent equity issuance and resulting dilution, including ATM sales and outstanding options and warrants.
- Whether PLACCINE advances to human testing, and how preclinical findings translate into clinical safety, efficacy, stability, and partnering prospects.
- The status and potential financial exposure of the remaining shareholder, books-and-records, and manufacturing-invoice disputes; the filing does not provide clear loss estimates for these matters.